Genmab US - GMAB Quarterly EPS earnings growth

Corporate company logo of Genmab (GMAB)

Due to a stable Danish legal environment and the absence of sanctions risks, Genmab A/S (GMAB) quarterly earnings per share demonstrate steady momentum, with the indicator reaching -15.00. Market capitalization is based on royalty payments from Darzalex therapy. Jan van de Winkel's management is betting on conservative alliances with pharma behemoths to effectively commercialize its unique antibodies.

genmab.com (GMAB) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/10/2026

Analytical breakdowns for Genmab A/S

- share price and consensus valuation forecast:
Stock Quotes Genmab|GMAB - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Genmab US|GMAB - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Genmab|GMAB - Accounting Value of Company|Market Capitalization to Book Value Ratio genmab.com|GMAB - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Capital Genmab A/S|GMAB - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Genmab A/S|GMAB - Company Cumulative Indebtedness|Debts to Book Capitalization Genmab US|GMAB - Long-Term Debt|Company Short-Term Debts Genmab|Quick Liquidity Indicator genmab.com
- earnings and market multiples details:
GMAB - Final Profit|Future Profit Genmab A/S|GMAB - Market Price to Net Income Ratio|Forward P/E Multiple Genmab US|GMAB - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Genmab US|GMAB - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Genmab|GMAB - Earnings per share for the trailing year|Quarterly EPS earnings growth genmab.com|GMAB - Earnings growth in current year|Net earnings per share growth forecast for next year Genmab A/S
Fundamental company valuation:Genmab - GMAB
Flagship merchandise of genmab.com

Professional asset selection is based on identifying proven financial stability. This indicator measures the percentage change in earnings per share (EPS) between reporting periods, revealing the actual efficiency of capital generation. The recorded quarterly EPS dynamics allow for an assessment of the business's operational strength. For Genmab A/S (GMAB), this trend reflects the success of clinical trials and the monetization of partnerships with pharma behemoths. The steady growth of this metric confirms the viability of the anti-cancer therapies under development.

Analysis of competing companies

EXEL (Exelixis) - Year-over-year net earnings per share growth for the last 12 months|NUVL: Year-over-year earnings per share growth rate for the last twelve months|KYMR (Kymera Therapeutics Inc) - Quarterly EPS earnings growth|Quarterly EPS earnings growth IDEAYA Corp|Year-over-year earnings per share growth for the last twelve months Enliven Therapeutics (ELVN)|ORIC (oricpharma.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth RLAY (Relay Therapeutics, Inc.)|Net earnings per share growth for the trailing year Nurix Therapeutics Inc|Tyra Bio - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Verastem Corp|GLUE (Monte Rosa Therapeutics) - Year-over-year net earnings per share growth for the last 12 months|CGEM: Year-over-year earnings per share growth rate for the last twelve months|IMRX (Immuneering) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Therapeutics Inc CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Bio Green Med Solution Inc. - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months GlycoMimetics Corp GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks Therapeutics, Inc. (SWTX)